UK and India sign agreement to help ensure drug quality

By Dan Stanton contact

- Last updated on GMT

MHRA and CDSCO sign memorandom of understanding
MHRA and CDSCO sign memorandom of understanding

Related tags: Contract

The MHRA has signed a Memorandum of Understanding (MOU) with Indian regulators to help ensure the quality of drugs in the UK.

The agreement, signed today, is the first between India’s Central Drugs Standard Control Organisation (CDSCO) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and intends to increase collaboration and strengthen ties between the two countries by promoting each other’s regulatory framework, requirements and processes

But the MoU will also help to ensure the safety of drug products imported from India into the UK, according to MHRA Chairman Sir Michael Rawlins.

“It’s essential that the commitment to good quality manufacturing comes right down from the top levels of management to those on the factory floor, and throughout the entire industry,” ​he said in a statement.

“Indian firms already accept and understand this, and the MOU is part of a concerted effort to ensure the UK and wider global public continue to have access to quality and safe medicines.”

A spokesman told this publication "the MoU won’t have a direct impact on the day to day running of the MHRA.  Rather it serves as a statement to cement our already existing working relationship with India and to provide a platform from which to further develop that partnership."

Quality Concerns

There have been a number of concerns surrounding the quality of Indian-made drugs and drug products.

A number of facilities have been hit with warning letters and import alerts due to cGMP violations, Wockhardt​ and Ranbaxy​ being two of the most high-profile over the past few years. But smaller API makers​ and contract services firms such as GVK BioSciences​ have also been accused of data integrity issues.

According to the India Brand Equity Foundation (IBEF), India supplies around 25% of all UK medicines.

Despite this, just 49 of the 675 inspections (about 7%) carried out by the UK agency in 2014 were in India. The MHRA told in-Pharmatechnologist the MoU would not directly impact the number of inspections undertaken.

Related news

Show more

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Related suppliers

Follow us


View more